Appoints Renown Neural Stem Cell Researcher, Dr. Brent Reynolds, PhD., As First Board Member
DENVER, Dec. 1, 2016 /Weed Wire/ — United Cannabis Corporation (OTCQB: CNAB) (the “Company” or “United Cannabis”) today announced the formation of an Advisory Board, as well as the appointment of Dr. Brent A. Reynolds, Ph.D. as the first member. Prior to this, Dr. Reynolds has been the Chief Medical Advisor at United Cannabis Corporation since May 2014 and served as its Director of Discovery Research & Development.
United Cannabis established the Advisory Board to help the Company advance and protect the development of its proprietary formulations, including managing the clinical trial process, patent protection, new product research and development, as well as identifying and pursuing potential strategic relationships.
Dr. Reynolds co-founded and was VP-Research of the world’s first neural stem cell company, NeuroSpheres, Ltd., where he developed a patent portfolio and protocols related to the application of neural stem cells to treating disorders of the central nervous system. Dr. Reynolds has held multiple academic and industry posts including Adjunct Professor at the University of New South Wales, Sydney, Australia; an Honorary Professor at the Queensland Brain Institute, Australia; and Program Director for StepAhead, Australia. He is currently a Professor in the Department of Neurosurgery at the University of Florida, College of Medicine where his lab focuses on the application of natural products for treating diseases and dysfunction of the nervous system. Dr. Reynolds received his PhD from the University of Calgary where he co-discovered the existence of stem cells in the adult mammalian brain.
Commenting on the appointment, Dr. Reynolds stated, “Although cannabis has been used as medicine for centuries, its interaction with and effects on the endocannabinoid system are just beginning to be understood by the scientific community. Unique to United Cannabis is their robust scientific approach to developing cannabinoid medicines. I am pleased to be a part of their effort to discover and develop therapies for the treatment of a number of conditions and diseases.”
Tony Verzura, Chief Technology Officer of United Cannabis, added, “Dr. Reynolds was a mentor for us during the creation of our Advance Cannabinoid Therapy Program (A.C.T. Now), and our patent-pending phyto-therapeutic approach to creating our entire medicinal line of products. Dr. Reynolds has numerous peer-reviewed publications, issued patents, tremendous credibility, and global experience within the scientific community.”
About United Cannabis Corporation
The Company’s Prana Bio Medicinal products provide patients a way to mix/match cannabinoids for therapeutic purpose. These products, licensed to regulated marijuana dispensaries, are broken into 5 categories that are available in capsules, sublingual’s, and topical delivery methods. The Company uses a patent-pending infusion process utilizing select fatty acids, lipids, and specific combination of cannabis derived terpenes to increase bioavailability.
For further information, please visit www.unitedcannabis.us.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors, created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.